Ponesimod Patent Expiration
Ponesimod is used for reducing circulating lymphocytes in treating relapsing forms of multiple sclerosis in adults. It was first introduced by Vanda Pharmaceuticals Inc
Ponesimod Patents
Given below is the list of patents protecting Ponesimod, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ponvory | US10220023 | Dosing regimen for a selective S1P1 receptor agonist | Dec 10, 2035 | Vanda Pharms Inc |
| Ponvory | US11951097 | Methods of treating multiple sclerosis | Oct 10, 2042 | Vanda Pharms Inc |
| Ponvory | US8273779 | Thiazolidin 4-one derivatives | Dec 17, 2025 | Vanda Pharms Inc |
| Ponvory | US9000018 | Thiazolidin-4-one-derivatives | Nov 16, 2024 | Vanda Pharms Inc |
| Ponvory | US9062014 | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one | May 06, 2032 | Vanda Pharms Inc |
| Ponvory | USRE43728 | Thiazolidin-4-one derivatives | Nov 16, 2024 | Vanda Pharms Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳